%0 Journal Article %J Am J Hematol %D 2016 %T Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Associ %A Svahn, Johanna %A Bagnasco, Francesca %A Cappelli, Enrico %A Onofrillo, Daniela %A Caruso, Silvia %A Corsolini, Fabio %A De Rocco, Daniela %A Savoia, Anna %A Longoni, Daniela %A Pillon, Marta %A Marra, Nicoletta %A Ramenghi, Ugo %A Farruggia, Piero %A Locasciulli, Anna %A Addari, Carmen %A Cerri, Carla %A Mastrodicasa, Elena %A Casazza, Gabriella %A Verzegnassi, Federico %A Riccardi, Francesca %A Haupt, Riccardo %A Barone, Angelica %A Cesaro, Simone %A Cugno, Chiara %A Dufour, Carlo %X

We analyzed 97 Fanconi anemia patients from a clinic/biological database for genotype, somatic, and hematologic phenotype, adverse hematological events, solid tumors, and treatment. Seventy-two patients belonged to complementation group A. Eighty percent of patients presented with mild/moderate somatic phenotype and most with cytopenia. No correlation was seen between somatic/hematologic phenotype and number of missense mutations of FANCA alleles. Over follow-up, 33% of patients improved or maintained mild/moderate cytopenia or normal blood count, whereas remaining worsened cytopenia. Eleven patients developed a hematological adverse event (MDS, AML, pathological cytogenetics) and three developed solid tumors. 10 years cumulative risk of death of the whole cohort was 25.6% with median follow-up 5.8 years. In patients eligible to hematopoietic stem cell transplantation because of moderate cytopenia, mortality was significantly higher in subjects transplanted from matched unrelated donor over nontransplanted subjects, whereas there was no significant difference between matched sibling donor transplants and nontransplanted patients. In patients eligible to transplant because of severe cytopenia and clonal disease, mortality risk was not significantly different in transplanted from matched unrelated versus matched sibling donor versus nontransplanted subjects. The decision to transplant should rely on various elements including, type of donor, HLA matching, patient comorbidities, impairment, and clonal evolution of hematopoiesis. Am. J. Hematol. 91:666-671, 2016. © 2016 Wiley Periodicals, Inc.

%B Am J Hematol %V 91 %P 666-71 %8 2016 Jul %G eng %N 7 %1 http://www.ncbi.nlm.nih.gov/pubmed/27013026?dopt=Abstract %R 10.1002/ajh.24373 %0 Journal Article %J Birth Defects Res A Clin Mol Teratol %D 2015 %T Clinical aspects of Fanconi anemia individuals with the same mutation of FANCF identified by next generation sequencing. %A Nicchia, Elena %A Benedicenti, Francesco %A Rocco, Daniela De %A Greco, Chiara %A Bottega, Roberta %A Inzana, Francesca %A Faleschini, Michela %A Bonin, Serena %A Cappelli, Enrico %A Mogni, Massimo %A Stanzial, Franco %A Svahn, Johanna %A Dufour, Carlo %A Savoia, Anna %X

BACKGROUND: Fanconi anemia (FA) is a rare genetic disease characterized by congenital malformations, aplastic anemia and increased risk of developing malignancies. FA is genetically heterogeneous as it is caused by at least 17 different genes. Among these, FANCA, FANCC, and FANCG account for approximately 85% of the patients whereas the remaining genes are mutated in only a small percentage of cases. For this reason, the molecular diagnostic process is complex and not always extended to all the FA genes, preventing the characterization of individuals belonging to rare groups.

METHODS: The FA genes were analyzed using a next generation sequencing approach in two unrelated families.

RESULTS: The analysis identified the same, c.484_485del, homozygous mutation of FANCF in both families. A careful examination of three electively aborted fetuses in one family and one affected girl in the other indicated an association of the FANCF loss-of-function mutation with a severe phenotype characterized by multiple malformations.

CONCLUSION: The systematic use of next generation sequencing will allow the recognition of individuals from rare complementation groups, a better definition of their clinical phenotypes, and consequently, an appropriate genetic counseling. Birth Defects Research (Part A) 103:1003-1010, 2015. © 2015 Wiley Periodicals, Inc.

%B Birth Defects Res A Clin Mol Teratol %V 103 %P 1003-1010 %8 2015 Dec %G ENG %N 12 %1 http://www.ncbi.nlm.nih.gov/pubmed/26033879?dopt=Abstract %R 10.1002/bdra.23388 %0 Journal Article %J Cytokine %D 2015 %T Impaired immune response to Candida albicans in cells from Fanconi anemia patients. %A Parodi, Alessia %A Kalli, Francesca %A Svahn, Johanna %A Stroppiana, Giorgia %A De Rocco, Daniela %A Terranova, Paola %A Dufour, Carlo %A Fenoglio, Daniela %A Cappelli, Enrico %K Adolescent %K Candida albicans %K CD8-Positive T-Lymphocytes %K Cell Proliferation %K Cells, Cultured %K Child %K Child, Preschool %K Cytokines %K Fanconi Anemia %K Humans %K Immunity %K Infant %K Young Adult %X

Fanconi anemia (FA) is a genetic disorder characterized by bone marrow failure and cancer predisposition. Several studies show alterations of the immunological status of FA patients including defects in peripheral blood lymphocyte subsets, serum immunoglobulin levels, and inflammatory cytokines. However scanty information is available on the response of FA cells to specific infectious antigens. In this work we examined the response of FA cells to different immunological stimuli and found a defective response of IL-1β, TNF-α and IL-17 to Candida albicans stimulation thus pointing to a potentially impaired response to fungal infections of FA patients.

%B Cytokine %V 73 %P 203-7 %8 2015 May %G eng %N 1 %1 http://www.ncbi.nlm.nih.gov/pubmed/25769809?dopt=Abstract %R 10.1016/j.cyto.2015.02.016 %0 Journal Article %J Haematologica %D 2014 %T Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology. %A De Rocco, Daniela %A Bottega, Roberta %A Cappelli, Enrico %A Cavani, Simona %A Criscuolo, Maria %A Nicchia, Elena %A Corsolini, Fabio %A Greco, Chiara %A Borriello, Adriana %A Svahn, Johanna %A Pillon, Marta %A Mecucci, Cristina %A Casazza, Gabriella %A Verzegnassi, Federico %A Cugno, Chiara %A Locasciulli, Anna %A Farruggia, Piero %A Longoni, Daniela %A Ramenghi, Ugo %A Barberi, Walter %A Tucci, Fabio %A Perrotta, Silverio %A Grammatico, Paola %A Hanenberg, Helmut %A Della Ragione, Fulvio %A Dufour, Carlo %A Savoia, Anna %K Amino Acid Substitution %K Cell Line %K Cohort Studies %K Computational Biology %K Databases, Nucleic Acid %K Fanconi Anemia %K Fanconi Anemia Complementation Group Proteins %K Founder Effect %K Genotype %K Humans %K Italy %K Mosaicism %K Mutation %K Polymorphism, Single Nucleotide %X

Fanconi anemia is an inherited disease characterized by congenital malformations, pancytopenia, cancer predisposition, and sensitivity to cross-linking agents. The molecular diagnosis of Fanconi anemia is relatively complex for several aspects including genetic heterogeneity with mutations in at least 16 different genes. In this paper, we report the mutations identified in 100 unrelated probands enrolled into the National Network of the Italian Association of Pediatric Hematoly and Oncology. In approximately half of these cases, mutational screening was carried out after retroviral complementation analyses or protein analysis. In the other half, the analysis was performed on the most frequently mutated genes or using a next generation sequencing approach. We identified 108 distinct variants of the FANCA, FANCG, FANCC, FANCD2, and FANCB genes in 85, 9, 3, 2, and 1 families, respectively. Despite the relatively high number of private mutations, 45 of which are novel Fanconi anemia alleles, 26% of the FANCA alleles are due to 5 distinct mutations. Most of the mutations are large genomic deletions and nonsense or frameshift mutations, although we identified a series of missense mutations, whose pathogenetic role was not always certain. The molecular diagnosis of Fanconi anemia is still a tiered procedure that requires identifying candidate genes to avoid useless sequencing. Introduction of next generation sequencing strategies will greatly improve the diagnostic process, allowing a rapid analysis of all the genes.

%B Haematologica %V 99 %P 1022-31 %8 2014 Jun %G eng %N 6 %1 http://www.ncbi.nlm.nih.gov/pubmed/24584348?dopt=Abstract %R 10.3324/haematol.2014.104224